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Abstract
Background: The capacity of electronic health record (EHR) data to guide targeted surveillance in chronic kidney
disease (CKD) is unclear. We sought to leverage EHR data for predicting risk of progressing from CKD to end-stage
renal disease (ESRD) to help inform surveillance of CKD among vulnerable patients from the healthcare safety-net.
Methods: We conducted a retrospective cohort study of adults (n = 28,779) with CKD who received care within
2 regional safety-net health systems during 1996–2009 in the Western United States. The primary outcomes were
progression to ESRD and death as ascertained by linkage with United States Renal Data System and Social Security
Administration Death Master files, respectively, through September 29, 2011. We evaluated the performance of 3
models which included demographic, comorbidity and laboratory data to predict progression of CKD to ESRD in
conditions commonly targeted for disease management (hypertension, diabetes, chronic viral diseases and severe
CKD) using traditional discriminatory criteria (AUC) and recent criteria intended to guide population health
management strategies.
Results: Overall, 1730 persons progressed to end-stage renal disease and 7628 died during median follow-up of 6.
6 years. Performance of risk models incorporating common EHR variables was highest in hypertension, intermediate
in diabetes and chronic viral diseases, and lowest in severe CKD. Surveillance of persons who were in the highest
quintile of ESRD risk yielded 83–94 %, 74–95 %, and 75–82 % of cases who progressed to ESRD among patients
with hypertension, diabetes and chronic viral diseases, respectively. Similar surveillance yielded 42–71 % of ESRD
cases among those with severe CKD. Discrimination in all conditions was universally high (AUC ≥0.80) when
evaluated using traditional criteria.
Conclusions: Recently proposed discriminatory criteria account for varying risk distribution and when applied to
common clinical conditions may help to inform surveillance of CKD in diverse populations.
Background
In the United States (US), progressive chronic kidney
disease (CKD) and particularly end-stage renal disease
(ESRD) disproportionately affect traditionally underserved
groups including racial-ethnic minorities and persons of
low socioeconomic means [1–6]. Despite the dispropor-
tionate burden of ESRD observed among racial-ethnic
minority and low income groups, effective interventions
to slow CKD progression and reduce mortality appear to
be underutilized in these populations [7, 8].
A central barrier to applying proven therapies in trad-
itionally underserved settings lies in the absence of
mechanisms to efficiently monitor and optimize care
provided to the nation’s poor and underinsured [9, 10].
Recently, one large safety-net health system has lever-
aged prediction analytics and data from the electronic
health record (EHR) to accurately identify inpatients with
specific conditions who are at high risk for subsequent
re-hospitalization [11]. Most patients with moderate or
severe CKD suffer from multiple chronic conditions and
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increasingly receive their care from Chronic Disease
Management teams [12, 13]. These clinic-based teams
typically target patients with specific conditions (e.g.,
diabetes mellitus, hypertension, chronic viral diseases,
congestive heart failure, severe CKD, etc.) and seek to
optimize important risk factors for progressive disease,
disability and mortality [13, 14]. However, even within
these clinic- or disease-based practices most individuals
with CKD will not progress to ESRD. Whether data
from the EHR can be “meaningfully” used to identify
persons at high risk for progressive CKD within this
practice-based construct is unclear.
To address this issue, we examined the performance of
EHR-based risk predictive models to discriminate among
persons with CKD who would and would not progress to
ESRD for time frames up to 7 years. We hypothesized that
the discriminatory ability (and usefulness) of these models
to accurately predict ESRD would vary substantially within
clinical subgroups due primarily to differences in patient
composition and in the distribution of ESRD risk.
Methods
Design, setting, and participants
We conducted a retrospective cohort study of 28,779
persons aged 18 years or older with non-dialysis requir-
ing CKD stages 3–5 who received healthcare in the San
Francisco Health Network (SFHN) or Harborview Med-
ical Center (HMC) from January 1, 1996 to December
31, 2009. Eligible subjects included prevalent patients
of SFHN or HMC with at least 2 or more ambulatory
serum creatinine measurements separated by at least
3 months. We defined CKD stage 3–5 based on the
presence of 2 or more serum creatinine measurements
yielding an estimated glomerular filtration rate (eGFR)
<60 mL/min/1.73 m2 as calculated by the re-expressed
Modification of Diet in Renal Disease (MDRD) study
equation based on calibrated serum creatinine, age, race
and sex that were separated by at least 3 months [15, 16].
To reduce the potential for exposure misclassification (i.e.,
acute kidney injury), we excluded inpatient serum creatin-
ine measurements from consideration. We elected to use
the MDRD eGFR (rather than more recently proposed
equations) to estimate kidney function because the MDRD
eGFR was reported by each health system’s clinical labora-
tory for most of the study period.
The SFHN (formerly Community Health Network) is the
integrated healthcare delivery system of the Department of
Public Health of the City and County of San Francisco [7].
During the study period, approximately half of San Francis-
co’s 130,000 uninsured residents and one-quarter of its
Medicaid population made at least one visit annually to the
SFHN. Harborview Medical Center in Seattle, Washington,
is the Pacific Northwest’s largest provider of care to medic-
ally underserved populations, providing over 20 % of all
uncompensated care in the state of Washington [17]. Both
health systems offer an array of healthcare services includ-
ing primary care, specialty care and acute care through
acute care hospitals (San Francisco General Hospital and
Harborview Medical Center) with on-site primary and spe-
cialty care clinics, as well as through community-based pri-
mary care clinics. Specialty care clinics include diabetes,
HIV, hypertension, and nephrology clinics. Services are
rendered irrespective of a patient’s ability to pay and fur-
ther include a wide range of interpreter services to facilitate
care for each system’s diverse patient population. Specific
details of the health systems have been previously de-
scribed [18].
Outcome measures and data sources
The primary outcome measure was progression to ESRD,
defined as having a first service date for maintenance dia-
lysis or kidney transplantation. We ascertained ESRD by
performing linkage with the United States Renal Data
System (USRDS) files based on patient name, date of birth
and Social Security number [1]. To ascertain death, we
performed identifier matching with the Social Security
Administration Master Death files using the same patient
identifiers described above [19]. We assessed ESRD and
death through September 29, 2011, the last date that data
were available for both outcomes at the time of identifier
linkage. We defined survival time as time from the first
qualifying serum creatinine date until ESRD, death or the
end of follow-up through September 29, 2011, whichever
occurred first.
Independent variables
We extracted sociodemographic and clinical variables
that we hypothesized might predict progression of CKD
to ESRD based on prior studies. These covariates were
defined within the 2-year period closest to the index
qualifying serum creatinine measurement (used to
calculate initial qualifying eGFR). Individual-level socio-
demographic covariates included patient age, sex, race-
ethnicity (non-Hispanic white, non-Hispanic black,
Hispanic, Asian/Pacific Islander, or other), and health
insurance coverage (uninsured, Medicaid, Medicare, or
commercial insurance) at the time of initial qualifying
eGFR. We ascertained comorbid conditions based on
established algorithms using discharge diagnostic codes,
ambulatory diagnostic codes and procedural codes for
diabetes mellitus, hypertension, cardiovascular disease
(defined as coronary artery, cerebrovascular, or peripheral
vascular disease), chronic viral disease (hepatitis B virus
[HBV], hepatitis C virus [HCV], or HIV/AIDS), and drug
or alcohol abuse [20–23]. Laboratory covariates included
eGFR, hemoglobin, serum albumin, calcium, cholesterol,
and phosphorus concentrations, and the presence and
severity of proteinuria according to dipstick urinalysis.
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Statistical approach
We summarized the characteristics of the cohort using
means (standard deviations) and proportions. We calcu-
lated unadjusted incidence rates of ESRD for the full
cohort, and for clinical subgroups defined by diabetes
mellitus, hypertension, chronic viral diseases (HBV, HCV
and/or HIV) and severe CKD (<30 mL/min/1.73 m2). We
focused on these four subgroups because they represent
common conditions frequently targeted by our Chronic
Disease Management programs. To approximate our
disease-based clinical practice, we did not require the sub-
groups to be mutually exclusive. Based on prior studies,
we tested three proportional hazards regression models to
predict progression to ESRD in each subgroup [24–26].
Model 1 included eGFR, dipstick proteinuria, and the “re-
sidual” associations with age, sex, and race-ethnicity. To
this model, we added health insurance coverage, comor-
bidities (diabetes mellitus, CVD, hypertension, substance
abuse and chronic viral disease) (model 2) and additional
laboratory variables (serum albumin, calcium, cholesterol
and hemoglobin) (model 3) [18].
To evaluate the predictive capacity of the models we
used 2-fold cross validation, training and validating our
models on separate subsets of the data [27]. We divided
each cohort into training and validation sets (2/3 and 1/
3 of each cohort, respectively). To reduce potential bias
caused by excluding patients with missing data, we per-
formed multiple imputation by chained equations with
10 imputations in the training and validation sets separ-
ately using the R package ‘mice’ based on observed vari-
ables related to the missingness (i.e., missing at random)
[28, 29]. We fitted each model to the 10 training sets,
and estimated the hazard ratios and the 95 % confidence
intervals taking into account the variability associated
with the multiple imputation. The baseline hazard func-
tion and the estimated coefficients for each model fit to
the training set were fixed and applied to the validation
set in order to obtain the probability of ESRD-free
survival beyond year 1, 3, 5 and 7 for each subject in the
validation set. We applied this procedure to each of the
10 imputed training-validation dataset pairs. We then
applied the following discrimination and calibration cri-
teria to assess the predictive performance of our model
on each subgroup: (1) receiver operating characteristics
(ROC) curve and the area under the ROC curve (AUC)
[30]; (2) prediction error (PE) [31]; (3) proportion of
cases followed (PCF(q)), and (4) proportion of the popu-
lation needed to be followed (PNF(p)) [32]. PCF and
PNF are pragmatic measures of risk concentration that
are directly relevant to public health decision-making
[32]. The PCF(q) represents the estimated proportion of
cases (or events) that would be captured if we followed
proportion q of the population at highest risk. PNF(p)
represents the estimated proportion of the population at
highest risk that would need to be followed in order to
capture proportion p of the events. Larger values of PCF
and smaller values of PNF indicate better predictive per-
formance [32].
Results
Patient characteristics
Consistent with US safety-net healthcare settings, the
CKD cohort was young (mean age 60 years) and had a
high proportion (59 %) of individuals from racial-ethnic
minority groups (Table 1). Among clinical subgroups, the
chronic viral disease subgroup was the youngest and had
the highest prevalence of substance abuse and mental
health conditions as compared with the other three sub-
groups (Table 1). In contrast, the hypertension subgroup
was the oldest and had the highest prevalence of cardio-
vascular disease. Men comprised a majority of patients
with chronic viral disease and severe CKD (eGFR <30 ml/
min/1.73 m2), and women comprised over half of patients
in the hypertension and diabetes mellitus subgroups.
Biochemically, the severe CKD subgroup had higher
(mean serum) concentrations of phosphorus, and lower
concentrations of albumin, calcium and hemoglobin as
compared with the other subgroups (Table 1).
ESRD risk distribution
Figure 1a and b show the estimated risk distribution for
ESRD in the hypertension and severe CKD subgroups
for time frames up to 7 years using the base model (age,
race, sex, eGFR and dipstick proteinuria). In the Figures,
80 and 90 % of the ESRD progressors at highest pre-
dicted risk are shown to the right of the vertical solid
grey line (q80) and vertical dashed line (q90), respect-
ively. In the hypertension subgroup, the base model dis-
criminated progressors (blue line) from non-progressors
(red line) well as reflected by little overlap in their re-
spective risk distribution for q80 and q90. In contrast,
substantial overlap in the distribution of ESRD among
progressors and non-progressors was observed using
the same model in the severe CKD subgroup (Fig. 1b).
Similar to hypertension, largely favorable separation
in risk distribution was observed in the chronic viral
disease and diabetes mellitus subgroups (Additional
file 1: Figures S1 and S2).
ESRD model performance
Overall, 1730 persons initiated ESRD treatment and
7628 died during median follow-up of 6.6 years (Table 2).
Persons with severe CKD experienced the highest and
persons with hypertension the lowest incidence rates of
ESRD among all subgroups (Table 2). Nearly 1 in 3 pa-
tients in the severe CKD subgroup progressed to ESRD as
compared with approximately 1 in 14 in the hypertension
and 1 in 9 in the diabetes mellitus subgroups.
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In the full cohort, models that included five common
variables (age, race, sex, eGFR, dipstick proteinuria)
from the EHR performed well in discriminating progres-
sors and non-progressors, whereby surveillance of indi-
viduals in the highest quintile of ESRD risk yielded 97,
91, 86 and 81 % of cases at years 1, 3, 5 and 7, respect-
ively as estimated by PCF(0.2) (Table 3). A predictive
model which included these five variables performed
similarly well in the hypertension and modestly lower in
the chronic viral disease and diabetes mellitus subgroups
(Fig. 2). Model performance was substantially lower in
the subgroup with severe CKD. Using the base model
(age, race, sex, eGFR and dipstick proteinuria), surveil-
lance of individuals in the highest quintile of ESRD risk
Table 1 Baseline characteristics of 28,779 patients with moderate or severe chronic kidney disease (stage 3–5) from the healthcare
safety net
Characteristics All Hypertension Diabetes mellitus Chronic viral diseasesa Severe CKDb
N = 28,779 n = 13,525 n = 6569 n = 5919 n = 2108
Demographics
Age, years, mean (sd) 60 (14) 62 (12) 60 (12) 54 (13) 58 (16)
Male, % 48 46 47 61 59
Race or ethnicity, %
White 41 34 32 44 36
Black 17 22 22 25 28
Hispanic 12 13 16 11 11
Asian 22 27 26 17 18
Other race or ethnicity 8 3 4 3 6
Additional Comorbidities, %
Cardiovascular disease 28 45 45 32 33
Chronic lung disease 30 37 36 31 31
Substance abuse 23 27 26 45 33
Depression 31 37 38 37 31
Health Insurance Coverage, %
Commercial/employer group 13 10 10 6 8
Medicaid 22 25 26 36 29
Medicare 37 43 41 33 32
Uninsured 29 23 23 25 31
Laboratory Measuresc
eGFRd, ml/min/1.73 m2, mean (sd) 49.0 (10.7) 49.0 (10.7) 48.6 (11.0) 48.2 (11.7) 20.1 (7.4)
Dipstick proteinuria
None or trace 62 63 56 57 30
1+ 19 18 18 22 24
2+ 12 11 14 13 24
≥ 3+ 8 8 12 8 23
Cholesterol, mmol/L, mean (sd) 5.1 (1.4) 5.1 (1.3) 5.0 (1.5) 4.7 (1.5) 4.8 (2.1)
Albumin, g/L, mean (sd) 37.8 (6.9) 38.3 (6.9) 37.5 (7.2) 35.9 (8.4) 32.5 (8.9)
Phosphorus, mmol/L, mean (sd) 1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 1.6 (0.7)
Calcium, mmol/L, mean (sd) 2.3 (0.2) 2.3 (0.2) 2.3 (0.2) 2.2 (0.2) 2.2 (0.3)
Hemoglobin, g/L, mean (sd) 129.3 (20.2) 129.7 (19.1) 127.2 (19.1) 124.2 (23.0) 114.4 (23.4)
Missing values in the full cohort were distributed as follows: dipstick proteinuria, 28.3 %; serum cholesterol, 15.1 %; serum calcium, 5.9 %; serum albumin, 1.9 %;
and hemoglobin, 1.8 %. HIV, hepatitis C virus, and/or hepatitis B virus infection
Patients with multiple comorbidities among hypertension, diabetes mellitus, chronic viral diseases and severe CKD are included in each category (i.e., counts for
the major comorbid categories listed in the columns above may overlap)
aHIV, hepatitis C virus, and/or hepatitis B virus infection
bChronic kidney disease stages 4–5
cLaboratory values represent serum concentrations unless noted otherwise
dEstimated glomerular filtration rate
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yielded an estimated 71 % of ESRD events occurring
within 1 year in persons with severe CKD. The corre-
sponding PCF(0.2) values declined to 57, 48 and 42 %
(ESRD events captured) for the 3-, 5-, and 7-year time
frames, respectively (Table 3). Notably, discrimination
based on traditional criteria was generally favorable in all
subgroups including in severe CKD (AUC, 0.80–0.87)
using the same model (note: models with AUC values
<0.70, with 0.50 being random and 1.00 being perfect, are
considered to have only moderate ability to discriminate
risk for an individual patient) [30]. Similar performance
patterns and covariate estimates were observed for more
complex models 2 and 3 (Additional file 1: Tables S1-S3).
Discussion
Surveillance of “real-world” care delivery to vulnerable
groups is challenging because kidney disease metrics are
not routinely measured or reported by federally qualified
health centers nor are they part of reporting require-
ments for health plans [33, 34]. Thus, underserved or
vulnerable patients with non-dialysis dependent CKD re-
main invisible to much of the healthcare system unless
Fig. 1 a The distributions of predicted risk of ESRD among persons with hypertension. The distributions of predicted risk of ESRD among subjects
who did not develop ESRD (non-progressors) in a given time frame is shown by the blue line and subjects who progressed to ESRD (progressors)
in that time frame is represented by the red line. We considered four time frames - 1 year, and 3, 5 and 7 years. 80 % of the ESRD progressors are
to the right of the vertical solid grey line (q80), and 90 % of them are to the right of the vertical dashed grey line (q90). The risk predictions are
based on application of a proportional hazards regression model incorporating age, race, sex, eGFR and dipstick proteinuria to the validation
dataset. b The distributions of predicted risk of ESRD among persons with severe CKD (eGFR < 30 ml/min/1.73 m2). The distributions of predicted
risk of ESRD among subjects who did not develop ESRD (non-progressors) in a given time frame is shown by the blue line and subjects who
progressed to ESRD (progressors) in that time frame is represented by the red line. We considered four time frames - 1 year, and 3, 5 and 7 years.
80 % of the ESRD progressors are to the right of the vertical solid grey line (q80), and 90 % of them are to the right of the vertical dashed grey
line (q90). The risk predictions are based on application of a proportional hazards regression model incorporating age, race, sex, eGFR and
dipstick proteinuria to the validation dataset
Table 2 Incidence rates of end-stage renal disease and death by comorbid subgroup among 28,779 patients with moderate or severe
chronic kidney disease from the healthcare safety net
Subgroup N at risk Time at risk x1000 person-years ESRD events Deaths ESRD rate
(per 1000 person-years)
Death rate
(per 1000 person-years)ESRD Death
All 28,779 198.8 220.5 1730 7628 8.7 34.6
Hypertension 13,525 91.1 101.5 1056 3715 11.6 36.6
Diabetes mellitus 6569 42.8 48.6 804 2060 18.8 42.2
Chronic viral diseasesa 5919 39.0 41.8 429 2126 11.2 50.9
Severe CKDb 2108 11.2 15.6 635 843 56.6 53.9
aHIV, hepatitis C virus, and/or hepatitis B virus infection
bChronic kidney disease stages 4–5 (estimated glomerular filtration rate <30 ml/min/1.73 m2)
Xie et al. BMC Nephrology  (2016) 17:57 Page 5 of 10
and until they reach ESRD (at which time most become
eligible for Medicare). In this diverse cohort of persons
with CKD, we observed that risk predictive models
using common data from the EHR can accurately
discriminated between most persons who did and did
not progress to ESRD for time frames up to 7 years.
However, the performance of these risk models varied
when applied to specific conditions frequently targeted
for Chronic Disease Management. Model performance
was highest in the hypertension subgroup, intermediate
in chronic viral disease and diabetes mellitus sub-
groups, and lowest in the subgroup with severe CKD
(eGFR < 30 ml/min/1.73 m2). Our study findings may
help health organizations and their clinical practices to
optimize care assessment by estimating the scope and
potential needs of patients with CKD who are at high-
est risk for disease progression, disability and ESRD-
related costs.
Health researchers frequently assess risk at the indi-
vidual level using epidemiological studies or by examin-
ing patient-level interventions in randomized clinical
trials [24–26]. Tangri et al. evaluated the performance
of several risk predictive models based on data extracted
from the EHR of 2 CKD cohorts in Canada using trad-
itional discriminatory criteria (C-statistic/AUC and inte-
grated discrimination improvement). They observed that
most ESRD risk predictive models performed well in
patients with moderate or severe CKD who were referred
for nephrology evaluation [24]. Complementary studies in
large study cohorts have yielded additional risk predictive
Table 3 Comparative performance of the base predictive model* for end-stage renal disease by comorbid subgroup among 28,779
patients with moderate or severe chronic kidney disease from the healthcare safety net
Measure All Hypertension Diabetes mellitus Chronic viral diseases Severe CKD
Year 1 AUC 0.97 (0.01) 0.97 (0.01) 0.97 (0.02) 0.89 (0.03) 0.87 (0.02)
PE 0.01 (0.00) 0.01 (0.00) 0.02 (0.00) 0.02 (0.00) 0.09 (0.02)
PCF (0.1) 0.91 (0.03) 0.95 (0.04) 0.88 (0.05) 0.71 (0.06) 0.44 (0.04)
PCF (0.2) 0.97 (0.02) 0.95 (0.03) 0.95 (0.04) 0.82 (0.05) 0.71 (0.04)
PNF (0.8) 0.05 (0.02) 0.04 (0.03) 0.07 (0.03) 0.18 (0.07) 0.26 (0.05)
PNF (0.9) 0.09 (0.05) 0.06 (0.05) 0.13 (0.06) 0.42 (0.12) 0.46 (0.07)
Year 3 AUC 0.94 (0.01) 0.94 (0.01) 0.94 (0.01) 0.91 (0.02) 0.87 (0.02)
PE 0.02 (0.00) 0.02 (0.00) 0.04 (0.01) 0.04 (0.00) 0.14 (0.04)
PCF (0.1) 0.83 (0.02) 0.82 (0.03) 0.68 (0.03) 0.71 (0.04) 0.34 (0.02)
PCF (0.2) 0.91 (0.02) 0.92 (0.03) 0.89 (0.03) 0.83 (0.04) 0.57 (0.03)
PNF (0.8) 0.08 (0.02) 0.09 (0.02) 0.14 (0.03) 0.17 (0.05) 0.39 (0.04)
PNF (0.9) 0.17 (0.04) 0.17 (0.06) 0.23 (0.06) 0.26 (0.08) 0.47 (0.05)
Year 5 AUC 0.92 (0.01) 0.94 (0.01) 0.92 (0.01) 0.92 (0.02) 0.83 (0.02)
PE 0.04 (0.00) 0.04 (0.01) 0.07 (0.01) 0.06 (0.01) 0.20 (0.06)
PCF (0.1) 0.74 (0.02) 0.73 (0.03) 0.57 (0.03) 0.64 (0.04) 0.27 (0.02)
PCF (0.2) 0.86 (0.02) 0.90 (0.02) 0.84 (0.02) 0.85 (0.04) 0.48 (0.03)
PNF (0.8) 0.13 (0.02) 0.13 (0.02) 0.16 (0.03) 0.17 (0.04) 0.45 (0.04)
PNF (0.9) 0.24 (0.04) 0.20 (0.05) 0.29 (0.05) 0.26 (0.08) 0.57 (0.04)
Year 7 AUC 0.90 (0.01) 0.90 (0.01) 0.88 (0.01) 0.88 (0.02) 0.80 (0.02)
PE 0.09 (0.01) 0.10 (0.02) 0.15 (0.03) 0.12 (0.02) 0.27 (0.08)
PCF (0.1) 0.64 (0.02) 0.64 (0.02) 0.47 (0.03) 0.53 (0.04) 0.23 (0.02)
PCF (0.2) 0.81 (0.02) 0.83 (0.02) 0.75 (0.03) 0.75 (0.04) 0.42 (0.03)
PNF (0.8) 0.19 (0.02) 0.18 (0.03) 0.27 (0.03) 0.24 (0.05) 0.47 (0.04)
PNF (0.9) 0.31 (0.04) 0.28 (0.05) 0.38 (0.05) 0.39 (0.07) 0.60 (0.04)
Estimates (standard errors) of the measures of predictive performance of proportional hazards regression model adjusted for age, sex, race-ethnicity, eGFR, dipstick
proteinuria and an interaction between eGFR and dipstick proteinuria. The model was fit to each of the ten imputed training sets and evaluated on each of the
corresponding validation sets. The ten multiply imputed training sets were based on two-thirds of the dataset (randomly selected, stratified on eGFR), the ten
multiply imputed validation sets were based on the remaining one-third of the study data for each subgroup (the imputations were performed separately on the
training and validation sets)
Abbreviations: AUC area under the ROC curve (measure of discrimination); PE prediction error (measure of calibration); PCF(q) proportion of cases followed if
proportion q of the population at highest risk is followed; PNF(p) proportion of the population at highest risk that needs to be followed to capture the proportion
p of the cases
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models for ESRD which are intended for use by clinicians
to estimate individual patient- rather than population-
level risk [25, 26]. Using criteria (proportion of cases
followed and proportion needed to follow) designed to
inform population-level disease assessment, we recently
observed that a model incorporating age, race, sex, eGFR
and dipstick proteinuria adequately predicted progres-
sion to ESRD among vulnerable persons with moderate
or severe CKD who were identified through systematic
review of the EHR [18]. Our current study findings extend
and leverage our prior work, by placing the proportion of
cases followed (PCF) and proportion of the population
needed to be followed (PNF) more squarely in the context
of how clinical care is actually delivered for this patient
population. Collectively, our observations suggest that
readily available data from the EHR might be efficiently
used in earlier stages of CKD to further inform care
assessment and planning for organizations or practices
based on clinical conditions commonly targeted by disease
management programs. For example, our methods could
be applied to hypertension clinic to estimate the potential
feasibility or effectiveness of an intervention or program
targeting of patients in the highest decile or quintile of
ESRD risk (e.g., for additional interventions or pragmatic
studies, etc.). The resources needed to follow a targeted
group of high-risk patients from such disease-based
program could be markedly lower than required for
risk-stratifying an entire health system. Because CKD
represents a heterogeneous array of underlying disease
states, this disease- or risk factor-based approach could
theoretically leverage existing programmatic resources
and infrastructure as an alternative to lumping all high-
risk CKD patients into a single category.
In terms of discriminatory assessment, our study illus-
trates how the PCF and PNF can be more informative
than traditional discriminatory criteria such as AUC by
providing estimates of risk concentration (for the event of
interest) in the study population. If risk is concentrated,
Fig. 2 Performance of the base model* for predicting progression of CKD to ESRD in different clinical conditions. The estimated proportion of
ESRD events captured (PCF) among a given proportion of subjects at highest estimated risk of ESRD (PNF) for a model* incorporating age, race,
sex, eGFR and dipstick proteinuria at 1, 3, 5 and 7-year time frames among persons with hypertension, chronic viral disease, diabetes mellitus and
severe CKD
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such as in the hypertension subgroup, values for trad-
itional discriminatory criteria will typically be large, but
the converse is not necessarily true [32]. In other words,
as observed in the severe CKD subgroup, values for trad-
itional discriminatory criteria may be favorable even when
risk is not concentrated [32, 35]. This observation occurs
because the AUC evaluates the model’s ability to discrim-
inate between progressors and non-progressors for all risk
thresholds, even those that are not as relevant in clinical
practice, such as risks close to zero. In contrast, when
using PCF and PNF, we can set the risk threshold at a clin-
ically meaningful level. Thus, desirable values of PCF and
PNF are achieved only if risk in the target population is
concentrated among a relatively small proportion of indi-
viduals (at highest risk). The suboptimal performance of
our risk models based on PCF/PNF values among persons
with severe CKD likely reflected the broader distribution
of ESRD risk in this subgroup. Notably, values for AUC
were universally favorable in all subgroups, and hence less
informative from the perspective of clinical practice. Re-
duced variance of influential predictors such as eGFR and
dipstick proteinuria among patients with severe CKD
(relative to patients from the other subgroups) likely fur-
ther reduced the predictive capacity of our risk models in
this subgroup. While the urinalysis dipstick remains an
excellent population-level screening tool for proteinuria,
its limited utility in predicting progression to ESRD
among patients in later stages of CKD has been previously
documented [36]. Thus, models which incorporate add-
itional predictors such urinary albumin-to-creatinine ratio
(which was measured only in a small fraction of patients
in our cohort) and annual decline in eGFR would likely
enhance predictive performance in the setting of severe
CKD. In addition, patients with severe CKD are also at
markedly higher risk of premature death than those with
higher levels of kidney function [20]. The elevated risk of
death in this severe CKD subgroup poses additional chal-
lenges for predicting ESRD since many (if not all) of the
covariates examined are also significantly associated with
death.
Historically, low individual-level provider and patient
awareness of CKD have reinforced the need to optimize
multi-level strategies (at the community, organization,
practice, and patient levels) to help assess and manage
CKD [18, 37–41]. Our study findings demonstrate the
potential usefulness of clinical data from the EHR to
provide reliable information for CKD care assessment at
the level of the organization and at the level of a disease-
or clinic-based practice which might readily generalize
to other chronic diseases. Accordingly, clinical practices
might leverage the EHR, for example, to identify, triage,
and monitor the care of patients at highest risk for pro-
gressing to ESRD. As evidenced by the high prevalence
of psychiatric conditions, drug and alcohol use in our
study cohort, such a multi-level health approach would
likely require the consideration of a broader array of
health determinants than in conventional health settings.
Intervention approaches might thus combine EHR-based
risk surveillance with facilitators of care engagement such
as assistance with transportation, housing, or health insur-
ance applications, drug or alcohol cessation programs,
and mental health co-management. When necessary, our
methods might also be applied to refer and track pa-
tients at highest risk for imminent (<1 year) ESRD to
ensure timely placement of dialysis access, transplant
referral, and dialysis education. Recent advancements
in software now enable predictive analytics to interdigi-
tate with the EHR, further highlighting the potential
“real world” and “real time” application of EHR-derived
predictive models [11].
Our study is strengthened by the inclusion of adults
with moderate or severe CKD from two large safety-net
health systems—populations which traditionally bear a
disproportionate burden of ESRD and which may benefit
from enhanced CKD surveillance. Our study also in-
cludes several limitations. First, while we were able to
provide detailed demographic and clinical data, and link
our cohort to national registries (to obtain complete or
nearly complete capture of treated ESRD and vital sta-
tus), our study was subject to potential bias from under-
ascertainment of comorbidities based on diagnostic and
procedural codes. Second, misclassification of CKD and
its severity using the MDRD GFR estimating equation
may also be operative since the MDRD study equation
was derived in a population of mostly white and black
patients with moderate-to-advanced CKD, very few of
whom had diabetes mellitus. Third, while our study in-
cluded patients from diverse social and demographic
groups, this cohort may not be fully representative of
patients who utilize the healthcare safety-net in other
geographic locations. In addition, our observations require
further validation using external data as our predictive
models may perform differently in other populations.
Lastly, rather than restricting our study to only patients
with complete data (and potentially introducing bias from
case deletion), we leveraged multiple imputation under
the assumption that missing values carried no information
about probabilities of missingness. However, our study
results may be potentially biased in the unlikely event
that this assumption of ‘missing at random’ (MAR)
was violated [29].
Conclusions
In conclusion, common variables from the EHR can be
leveraged to adequately discriminate among most patients
with CKD who will and will not progress to ESRD in this
safety-net healthcare setting. Recently developed discrim-
inatory criteria may be applied to evaluate the ability of
Xie et al. BMC Nephrology  (2016) 17:57 Page 8 of 10
risk predictive models to discriminate between progres-
sors and non-progressors only within a clinically relevant
range, and thus, help to inform CKD surveillance at mul-
tiple levels in diverse clinical settings.
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